Regeneron Pharmaceuticals Inc (STU:RGO)
€ 757 -6.6 (-0.86%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.51 PB Ratio: 3.11 GF Score: 98/100

Regeneron Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 24, 2021 / 03:40PM GMT
Release Date Price: €378.8 (-0.73%)
Geoffrey Craig Porges
SVB Leerink LLC, Research Division - Director of Therapeutics Research & Diversified Biopharma and Senior Research Analyst

Good morning, everybody. I'm Geoff Porges, Director of Therapeutics Research and Senior Biotech Analyst here at SVB Leerink. Welcome to what is now day 3 of our Global Healthcare Conference. I'm delighted to host our next company this morning, which is Regeneron. Regeneron is represented by Justin Holko, who is Vice President of Investor Relations; and Marion McCourt, who is Chief Commercial Officer. Marion and Justin, welcome to GHC. And Justin, I think you have a few remarks.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Geoff. Glad to join you today. Before we begin, I would like to remind you that remarks made on today's webcast do include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement. A more complete description of these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot